https://gsk-3signals.com/index.....php/orthogonal-cont
We explored the inclusion of carfilzomib, s second-generation proteasome inhibitor (20 mg/m2, intravenously on days +1 and +2) to cyclosporine/methotrexate anchor in 26 customers after SCT from unrelated donors. We compared effects to historic band of 100 patients provided cyclosporine/methotrexate alone. Median follow-up ended up being 34 months. There clearly was no difference between the groups in engraftment or toxicities. The cumulative incidence of aGVHD
Like
Comment
Share
